UBS Initiates Kyverna Therapeutics(KYTX.US) With Buy Rating, Announces Target Price $13
Kyverna Therapeutics Initiated at Buy by UBS
Kyverna Therapeutics Price Target Announced at $13.00/Share by UBS
Kyverna Therapeutics Analyst Ratings
Rodman & Renshaw Initiates Kyverna Therapeutics(KYTX.US) With Buy Rating, Announces Target Price $16
Kyverna Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on Kyverna Therapeutics, Maintains $7 Price Target
Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $40
H.C. Wainwright Maintains Kyverna Therapeutics(KYTX.US) With Hold Rating, Maintains Target Price $7
Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $40
J.P. Morgan Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $33
Kyverna Therapeutics Analyst Ratings
Analysts Offer Insights on NA Companies: Kyverna Therapeutics, Inc. (KYTX), Smith Douglas Homes Corp. Class A (SDHC) and Kayne Anderson BDC, Inc. (KBDC)
H.C. Wainwright Initiates Kyverna Therapeutics(KYTX.US) With Hold Rating, Announces Target Price $7
Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $40
Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $40
Kyverna Therapeutics Analyst Ratings
JP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $33
HC Wainwright & Co. Reiterates Neutral on Kyverna Therapeutics, Maintains $8 Price Target
Kyverna Therapeutics Analyst Ratings